CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition

Anti-EGFR therapy is used to treat metastatic colorectal cancer (CRC) patients, for which initial response rates of 10–20% have been achieved. Although the presence of HER2 amplifications and oncogenic mutations in KRAS, NRAS, and BRAF are associated with EGFR-targeted therapy resistance, for a larg...

Descripción completa

Detalles Bibliográficos
Autores principales: Post, Jasmin B., Hami, Nizar, Mertens, Alexander E.E., Elfrink, Suraya, Bos, Johannes L., Snippert, Hugo J.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402720/
https://www.ncbi.nlm.nih.gov/pubmed/30858928
http://dx.doi.org/10.18632/oncotarget.26677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402720/
https://www.ncbi.nlm.nih.gov/pubmed/30858928
http://dx.doi.org/10.18632/oncotarget.26677

Ejemplares similares